Cold-fX makers misled public, case should receive class-action approval: lawsuit

Cold-fX lawsuit seeks class-action approval

VANCOUVER — The makers of Cold-fX are in court fighting allegations they ignored their own research and misled consumers about the short-term effectiveness of the popular cold and flu remedy.

Valeant Pharmaceuticals (TSX:VRX) was in British Columbia Supreme Court on Monday, opposing an application to grant the lawsuit class-action status.

Vancouver Island resident Don Harrison launched a claim in 2012 against Valeant and its subsidiary, Afexa Life Sciences, over advertising saying that Cold-fX offered “immediate relief of cold and flu symptoms” if taken over a three-day period at the first sign of illness.

Harrison’s notice of claim said Valeant and Afexa continued to “knowingly or recklessly” promote Cold-fX despite evidence the natural-health product only had a possible positive impact after being taken daily for prolonged periods of two-to-six months.

“The gist of the case is that people paid money for a worthless product … and the money they spent should be returned,” said Harrison’s lawyer, John Green, in a interview.

Valeant also unnecessarily exposed its customers to a health threat by distributing a useless drug with a risk of adverse side effects, he said.

The Laval, Que.,-based company denied the accusations in a statement and said it will fight the application for class-action certification.

“Valeant believes the suit is without merit and is vigorously defending this matter,” said the document.

None of the allegations have been tested in court.

Afexa is the original manufacturer and licence holder of Cold-fX and was bought by Valeant in 2011.

Valeant has been marred by a succession of controversies in recent months that have sapped its stock value and hammered its reputation, leading the CEO of the embattled Quebec drugmaker to step down last month.

The series of setbacks include gouging customers by hiking drug prices and filing misstated earnings, the latter of which it blames on its former chief financial officer.

Green also alleged Valeant and Afexa kept quiet about an internal study conducted in the early 2000s that contradicted the health claims around Cold-fX.

“The defendants knew at least as early as 2004, when they had a study done themselves, that Cold-fX might be even less effective than a placebo,” he said. 

“The study actually showed the placebo to be more effective at relieving (some) cold symptoms than Cold-fX.”

The study found the product effectively reduced the severity of a runny nose during the early days of a respiratory infection, but that it had limited efficacy in treating other symptoms, particularly a cough and stuffy nose.

If the case receives class-action approval, anyone who bought Cold-fX for the short-term relief of cold and flu symptoms will be able to apply to a fund that will be created to get their money back, said Green.

He estimated the total to be refunded would amount to about $500 million. That calculation uses $50 million per year in estimated revenues for Valeant from Cold-fX, then assumes a 100-per-cent markup, over a five-year time period.

Because of differences in provincial law, a court victory in B.C. wouldn’t allow people outside the province who bought Cold-fX to make a claim, said Green. For that reason, an identical lawsuit has been launched in Saskatchewan, where a positive ruling would apply to everyone across the country.

A successful judgment from a B.C. representative plaintiff could be taken to Saskatchewan to bolster the case in that province, he said.

Valeant is expected to begin its defence on Tuesday or Wednesday.

— Follow @gwomand on Twitter

Geordon Omand, The Canadian Press

Just Posted

South Surrey church members ‘praying for accused mother… for the whole process’

Lisa Batstone’s second-degree murder trial continues this week in B.C. Supreme Court

City will ask Fraser Health to remove pay parking at SMH, Surrey councillor says

Surrey’s new council has already made parking free on neighbouring city streets

Health and Technology District breaks ground on new building

City Centre 3 is the third of eight planned buildings: Lark Group

Spawning salmon returning to North Delta’s Cougar Creek

It’s early in the season, but the streamkeepers are hopeful it could be a good year for returns

Surrey White Rock Ringette Association ‘excited’ about world championships coming to Lower Mainland

Ringette Canada says the sport has reached record registration numbers

Winter weather hits parts of Canada

As some parts of the country brace for cold, parts of B.C. remain warmer than 10 C

Canada’s health system commendable overall but barriers to care remain: UN

The United Nations says Canada’s health care system is “commendable” overall but vulnerable groups still face barriers to quality care.

Unique technology gives children with special needs more independent play

UVic’s CanAssist refined seven prototypes aided by $1.5M government contribution

Kelly Ellard’s boyfriend has statutory release revoked

Darwin Duane Dorozan had several parole infractions that found him ‘unmanageable’

New chair of Metro Vancouver board is Burnaby councillor

The 40-person board is made up of elected officials from 21 cities and one First Nation

Doctor’s note shouldn’t be required to prove you’re sick: poll

70% of Canadians oppose allowing employers to make you get a sick note

German-born B.C. man warns against a ‘yes’ vote on proportional representation

Agassiz realtor Freddy Marks says PR in his home country shows party elites can never be voted out

Fashion Fridays: 5 coats you need this winter!

Kim XO, lets you know the best online shopping tips during Fashion Fridays on the Black Press Media Network

Saskatchewan college honours memory of Humboldt Broncos coach

Darcy Haugan wore jersey No. 22 when he was a star player with the Briercrest College Clippers

Most Read